BR100 Increased By (0.01%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.38 Increased By ▲ 0.06 (0.95%)
BECO 4.35 Increased By ▲ 0.08 (1.87%)
BML 62.55 Increased By ▲ 0.10 (0.16%)
BOP 31.39 Increased By ▲ 0.16 (0.51%)
CNERGY 11.73 Increased By ▲ 0.14 (1.21%)
CSIL 5.91 Increased By ▲ 0.19 (3.32%)
FCCL 61.71 Increased By ▲ 0.17 (0.28%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.32 Increased By ▲ 0.06 (0.96%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.69 Increased By ▲ 0.01 (0.04%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.32 Decreased By ▼ -1.96 (-1.12%)
NCPL 51.83 Decreased By ▼ -0.94 (-1.78%)
NPL 54.03 Decreased By ▼ -0.09 (-0.17%)
OGDC 315.87 Increased By ▲ 2.48 (0.79%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.58 Decreased By ▼ -0.22 (-0.61%)
PIBTL 13.66 Increased By ▲ 0.19 (1.41%)
PPL 226.07 Increased By ▲ 4.26 (1.92%)
PRL 80.28 Increased By ▲ 1.20 (1.52%)
PTC 46.64 Decreased By ▼ -0.21 (-0.45%)
SSGC 23.82 Decreased By ▼ -0.05 (-0.21%)
TBL 9.24 Decreased By ▼ -0.07 (-0.75%)
TELE 7.55 Increased By ▲ 0.16 (2.17%)
TPL 24.54 Decreased By ▼ -0.57 (-2.27%)
TPLP 12.99 Increased By ▲ 0.48 (3.84%)
TREET 25.98 Decreased By ▼ -0.27 (-1.03%)
TRG 53.33 Decreased By ▼ -0.11 (-0.21%)
World

J&J's says its Covid-19 vaccine effectively combats Delta variant

  • The antibodies and immune system cells in the blood of eight people vaccinated with the J&J jab effectively neutralized the Delta strain
Published Updated
By

WASHINGTON: Johnson and Johnson's single-shot Covid-19 vaccine is effective against the highly contagious Delta variant, with an immune response lasting at least eight months, the company said Thursday.

The antibodies and immune system cells in the blood of eight people vaccinated with the J&J jab effectively neutralized the Delta strain, which was first identified in India, researchers found.

A second study with 20 vaccinated patients at Boston's Beth Israel Medical Center had similar results.

The data was sent to bioRxiv, a free online site for unpublished scientific preprints where authors "are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals," according to the site.

"We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant," said Paul Stoffels, J&J's chief scientific officer, in a company statement.

Mathai Mammen, head of Janssen Research & Development at Johnson & Johnson, said that data "for the eight months studied so far" shows that J&J's single-shot vaccine "generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time."

The Delta variant tore through in India in April and May and has since spread around the world. A report by the European Union's disease control agency ECDC estimated the more contagious strain could account for 90 percent of new cases in the EU by the end of August.

Comments

Comments are closed for this article.